Prostate cancer is a major public health concern worldwide, being one of the most prevalent cancers in men. Great improvements have been made both in terms of early diagnosis and therapeutics. However, there is still ...Prostate cancer is a major public health concern worldwide, being one of the most prevalent cancers in men. Great improvements have been made both in terms of early diagnosis and therapeutics. However, there is still an urgent need for reliable biomarkers that could overcome the lack of cancer-specificity of prostate-specific antigen, as well as alternative therapeutic targets for advanced metastatic cases. Reversible phosphorylation of proteins is a post-translational modification critical to the regulation of numerous cellular processes. Phosphoprotein phosphatase 1(PPP1) is a major serine/threonine phosphatase, whose specificity is determined by its interacting proteins. These interactors can be PPP1 substrates, regulators, or even both. Deregulation of this protein-protein interaction network alters cell dynamics and underlies the development of several cancer hallmarks. Therefore, the identification of PPP1 interactome in specific cellular context is of crucial importance. The knowledge on PPP1 complexes in prostate cancer remains scarce, withonly 4 holoenzymes characterized in human prostate cancer models. However, an increasing number of PPP1 interactors have been identified as expressed in human prostate tissue, including the tumor suppressors TP53 and RB1. Efforts should be made in order to identify the role of such proteins in prostate carcinogenesis, since only 26 have yet well-recognized roles. Here, we revise literature and human protein databases to provide an indepth knowledge on the biological significance of PPP1 complexes in human prostate carcinogenesis and their potential use as therapeutic targets for the development of new therapies for prostate cancer.展开更多
Although many tumor markers have been identified and studied in epithelial ovarian cancer,a potential and useful screening marker for ovarian cancer has not been yet clearly established. Ovarian cancer is considered a...Although many tumor markers have been identified and studied in epithelial ovarian cancer,a potential and useful screening marker for ovarian cancer has not been yet clearly established. Ovarian cancer is considered as a "silent killer"because of the absence of specific symptoms until late stage. Several validated biomarkers are currently used to diagnose and monitor the progression of the cancer,but very few of them show adequate specificity and sensitivity for different population screening. There is therefore an urge need to find biomarkers with high diagnostic accuracy and set up screening programs which can help detect ovarian cancer early,predict the response of the patient to anticancer therapy and guide physicians in choosing the best treatment for the patient. CA125,HE4 and STIP1 have been proven to play an important role as biomarkers in detecting and monitoring ovarian cancer. In this paper,we review evaluate,and highlight the role of CA125,HE4 and STIP1 in the detection of ovarian cancer.Potential biomarkers can help us distinguish malignancy from benign pelvic mass.展开更多
基金Supported by Fundao para a Ciência e Tecnologia(FCT)(PTDC/QUI-BIQ/118492/2010)Fundo Europeu de Desenvolvimento Regional(FEDER)(FCOMP-01-0124-FEDER-020895),Portugal
文摘Prostate cancer is a major public health concern worldwide, being one of the most prevalent cancers in men. Great improvements have been made both in terms of early diagnosis and therapeutics. However, there is still an urgent need for reliable biomarkers that could overcome the lack of cancer-specificity of prostate-specific antigen, as well as alternative therapeutic targets for advanced metastatic cases. Reversible phosphorylation of proteins is a post-translational modification critical to the regulation of numerous cellular processes. Phosphoprotein phosphatase 1(PPP1) is a major serine/threonine phosphatase, whose specificity is determined by its interacting proteins. These interactors can be PPP1 substrates, regulators, or even both. Deregulation of this protein-protein interaction network alters cell dynamics and underlies the development of several cancer hallmarks. Therefore, the identification of PPP1 interactome in specific cellular context is of crucial importance. The knowledge on PPP1 complexes in prostate cancer remains scarce, withonly 4 holoenzymes characterized in human prostate cancer models. However, an increasing number of PPP1 interactors have been identified as expressed in human prostate tissue, including the tumor suppressors TP53 and RB1. Efforts should be made in order to identify the role of such proteins in prostate carcinogenesis, since only 26 have yet well-recognized roles. Here, we revise literature and human protein databases to provide an indepth knowledge on the biological significance of PPP1 complexes in human prostate carcinogenesis and their potential use as therapeutic targets for the development of new therapies for prostate cancer.
文摘Although many tumor markers have been identified and studied in epithelial ovarian cancer,a potential and useful screening marker for ovarian cancer has not been yet clearly established. Ovarian cancer is considered as a "silent killer"because of the absence of specific symptoms until late stage. Several validated biomarkers are currently used to diagnose and monitor the progression of the cancer,but very few of them show adequate specificity and sensitivity for different population screening. There is therefore an urge need to find biomarkers with high diagnostic accuracy and set up screening programs which can help detect ovarian cancer early,predict the response of the patient to anticancer therapy and guide physicians in choosing the best treatment for the patient. CA125,HE4 and STIP1 have been proven to play an important role as biomarkers in detecting and monitoring ovarian cancer. In this paper,we review evaluate,and highlight the role of CA125,HE4 and STIP1 in the detection of ovarian cancer.Potential biomarkers can help us distinguish malignancy from benign pelvic mass.
